CHM

CHIMERIC FPO [CHM]
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Healthcare · ASX Small Cap
$0.1050 -4.6%

Updated 2 Jun 2026 · Signals refresh every scan

Get alerts when CHM triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track CHM — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Volume surging at 2.1x normal while price falls — heavy selling pressure
  • Lagging the Small Ords index — relative strength of 0.69, underperforming its peers
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Critical cash runway (1.2 quarters)
  • Low P/S ratio (0.6x)
  • Revenue in sharp decline (-53%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (1% of range)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 62% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.82%/day)
  • Altman Z-Score distress zone (-1.01 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)
  • Overseas risk_on (+2pts, S&P500 up, VIX 16)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-193%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -53% — the top line is shrinking

Recent Catalysts

NONE Application for quotation of securities - CHM
NONE CHM announces positive Phase 1/2 data at ASCO
NONE Application for quotation of securities - CHM
Announcement tone +3pts

Recent ASX Announcements

2026-06-01 Application for quotation of securities - CHM
2026-05-31 CHM announces positive Phase 1/2 data at ASCO PRICE SENSITIVE
2026-05-20 Application for quotation of securities - CHM
2026-05-12 Notice under section 708A
2026-05-12 Application for quotation of securities - CHM

Key Metrics

$5.4M
Market Cap
185K
Avg Volume
2.1x
Vol Ratio
$0.10 — $0.60
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-1291.0%
ROE
-192.7%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 51%
LLeader vs LaggardlaggardRS: -59
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

119 tickers in this sector

View all Healthcare signals →
Related Tickers
IBX +29.4%SLD +21.8%MEM +20.0%SHG +18.0%IPD -14.3%
Compare:CHM vs IBXCHM vs SLDCHM vs MEM
Share this analysis

Track CHM and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required